Billions of investment dollars to develop Michigan’s life sciences corridor and pharmaceutical research have not gone for naught: two major announcements show that Michigan has attracted national attention as a foremost leader in the booming life sciences market, and that trend isn’t about to end anytime soon.
According to excerpts from the story:
First, a California biotech company developing new genetic tests announced it's buying the Center for Molecular Medicine in Grand Rapids amid plans for a future new lab that may create up to 523 jobs by 2013.
The next day, the U.S. pharmaceutical industry's trade association unveiled a report in Michigan detailing the number of new drugs under development in America.
The Pharmaceutical Research and Manufacturers Association, or PhRMA, chose Michigan as the spot to release its report to highlight the state's growing role in the industry. Although the biotech industry in Michigan remains small compared to some other states, "we see it as a fertile ground," with its research and support infrastructure, education base and talent pool, which continues to build, said Ken Johnson, senior vice president of public affairs with the Washington, D.C.-based PhRMA.
Read the complete story here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.